These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
56 related articles for article (PubMed ID: 1463345)
1. [Salvage therapy for recurrent or refractory non-Hodgkin's lymphoma with etoposide, methotrexate, vindesine and prednisolone (EMVP)]. Sano F; Koike M; Nakamura K; Wakayama T; Kunika N; Kubomatsu Y; Katoh M; Chisa M; Hasegawa S; Takahashi M Gan To Kagaku Ryoho; 1992 Dec; 19(14):2389-93. PubMed ID: 1463345 [TBL] [Abstract][Full Text] [Related]
2. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma]. Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251 [TBL] [Abstract][Full Text] [Related]
3. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
5. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma]. Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071 [TBL] [Abstract][Full Text] [Related]
6. [MMIP chemotherapy for the treatment of the relapsed and refractory non-Hodgkin's lymphoma]. Takeshima M; Nakamura S; Mochizuki Y; Hattori N; Kaya H; Otake S; Okabe Y; Okumura H; Yoshida T; Matano S Rinsho Ketsueki; 1995 Feb; 36(2):106-14. PubMed ID: 7715081 [TBL] [Abstract][Full Text] [Related]
7. Salvage chemotherapy for non-Hodgkin's lymphoma with a combination of mitoxantrone, etoposide, cisplatin, and prednisolone. Ohnoshi T; Hayashi K; Ueoka H; Yamane T; Ueno K; Murashima M; Tada A; Yoshida M; Kimura I Cancer Treat Rep; 1987 Jun; 71(6):639-41. PubMed ID: 3581103 [TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357 [TBL] [Abstract][Full Text] [Related]
9. [Salvage combination chemotherapy with cytarabine, carboplatin and steroids for relapsed or refractory non-Hodgkin's lymphoma]. Yamamura R; Yamane T; Aoyama Y; Nakamae H; Hasegawa T; Ohta K; Nakao Y; Ohta T; Mugitani A; Hino M Gan To Kagaku Ryoho; 2004 Mar; 31(3):373-5. PubMed ID: 15045943 [TBL] [Abstract][Full Text] [Related]
10. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL). Coleman M; Leonard J; Shuster MW; Kaufman TP Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401 [TBL] [Abstract][Full Text] [Related]
11. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol]. Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405 [TBL] [Abstract][Full Text] [Related]
12. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474 [TBL] [Abstract][Full Text] [Related]
14. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma]. Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385 [TBL] [Abstract][Full Text] [Related]
15. [Treatment with ACVP-16 for relapsed and refractory non-Hodgkin's lymphoma]. Niitsu N; Hara A; Umeda M; Shirai T Rinsho Ketsueki; 1993 Jul; 34(7):829-34. PubMed ID: 7689661 [TBL] [Abstract][Full Text] [Related]
16. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma]. Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903 [TBL] [Abstract][Full Text] [Related]
17. [ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas]. Yoshida T; Nakanishi J; Ito K; Kobayashi K; Ohtake S; Nakamura S; Matsuda T; Nakagoshi T; Natori K; Nakamura E Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):984-9. PubMed ID: 3963862 [TBL] [Abstract][Full Text] [Related]
18. [Vindesine, CCNU, high-dosage ara-C, and prednisolone (VINAP regimen) in the treatment of relapsing or refractory non-Hodgkin's lymphomas]. Domingo Albós A; Callís M; Juliá A; Vilá J; Zuazu J; Puig J; Petit J; Fernández-Sevilla A Sangre (Barc); 1989 Apr; 34(2):107-11. PubMed ID: 2756450 [TBL] [Abstract][Full Text] [Related]
19. [Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders]. Miyazaki E; Takemoto Y; Kanamaru A; Kakishita E; Nagai K; Masaoka T; Shibata H; Horiuti A; Tsubaki K; Yonezawa T Gan To Kagaku Ryoho; 1992 Apr; 19(4):497-503. PubMed ID: 1558399 [TBL] [Abstract][Full Text] [Related]
20. [Salvage chemotherapy with a combination of VP-16, ifosfamide, procarbazine, prednisolone, bleomycin and methotrexate (VIPP-BM) for refractory malignant lymphoma]. Ohnishi K; Hotta T; Murate T; Inoue C; Ichikawa A; Ninomiya N; Goto S; Tsushita K; Utsumi M; Nagura E Rinsho Ketsueki; 1989 Mar; 30(3):289-96. PubMed ID: 2475652 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]